1 / 7

Drug Allergy Market Size, Share, Growth, Trend, Forecast to 2023 | COVID-19 Impact Analysis

Drug allergies are unpredictable reactions to intake of drugs. These can be triggered by herbal, prescription, and nonprescription drugs. Such drugs may be immunoglobulin E (IgE) or non-immunoglobulin E mediated. The global drug allergy market report by Market Research Future (MRFR) outlines pertinent drivers, challenges, trends, and opportunities for the forecast period of 2017 to 2023.

ketshubhra
Télécharger la présentation

Drug Allergy Market Size, Share, Growth, Trend, Forecast to 2023 | COVID-19 Impact Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Allergy Market Industry Analysis, Size, Share, Forecasts to 2023 | COVID-19 Impact Analysis PREPARED BY Market Research Future (Part of Wantstats Research & Media Pvt. Ltd.)

  2. Drug Allergy Market Drug Allergy Market – Overview The global drug allergy market size can touch USD 4,764 million by 2023 at a CAGR of 5.1% during the forecast period. Awareness of allergies and respective treatments coupled with the launch of new products can fuel the market demand. Investments in research and development to prevent allergic reactions will work in favor of the market. Development of diagnostic tests to come to accurate conclusions can save patient lives. For instance, the PEN-FAST prediction tool can predict allergies of patients to penicillin which go undetected with normal tests of skin or patch. Changes in lifestyles of consumers, alarming levels of indoor and outdoor pollution, and rapid urbanization have caused drug allergies among patients. According to the World Health Organization (WHO), the U.S. reported close to 40 million cases of inhaled allergies in 2012. Advances in technologies and rapid government approval of diagnostic tests can further the market growth till 2023. 2 www.marketresearchfuture.com

  3. Drug Allergy Market Drug Allergy Market Segmentation The global drug allergy market is segmented on the basis of type, diagnosis, treatment, and end user. • By type, it is segmented into immunologic, nonimmunologic, and others. Immunologic allergy is sub-segmented into type I reaction, type II reaction, type III reaction, type IV reaction, and others. The non-immunologic allergy is sub-segmented into predictable, unpredictable, and others. The predictable allergy is further segmented into pharmacologic side effect, secondary pharmacologic side effect, drug toxicity, drug-drug interactions, drug overdose, and others. The unpredictable segment is further sub-segmented into pseudoallergic, idiosyncratic, intolerance, and others. • By diagnosis, it is segmented into skin test, blood test, patch test, and others. Skin test is further segmented into intradermal test, scratch or prick test, and others. • By treatment, it is segmented into antihistamines, corticosteroids, withdrawal of the drug, treatment of anaphylaxis, and others. Antihistamines comprises azelastine eyedrops, levocabastine eyedrops, hydroxyzine, emedastine eyedrops, desloratadine, carbinoxamine, diphenhydramine, cyproheptadine, azelastine nasal sprays, levocabastine oral, and others. While corticosteroids are further segmented into inhaled steroids, topical steroids, and others. • By end user, it is segmented into academic institutes, medical research centers, hospitals & clinics, and others. Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Drug Allergy Market @ https://www.marketresearchfuture.com/sample_request/4033 3 www.marketresearchfuture.com

  4. Drug Allergy Market Global Drug Allergy Market – Geographical Analysis The Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) are regions of interest covered in the global drug allergy market. The Americas comprise North America and Latin America, out of which the former drives the market growth. The North America drug allergy market is driven by the U.S. Nearly 10% of the U.S. population suffer from drug allergies which can trigger market demand till 2023. On the other hand, Latin America can display a moderate growth rate during the forecast period owing to Chile, Argentina, and Brazil. Europe is driven into Western and Eastern Europe. Western Europe is accountable for major market share of the Europe drug allergy market. Increasing cases of drug allergies are the primary driver. APAC can exhibit the fastest growth rate during the forecast period owing to improvements in drug testing facilities, accurate assays, and awareness of drug allergies. Japan currently leads the APAC market, while China is portended to showcase a robust pace. The Chinese growth is marked by continuous inflow of capital, high industrial output, and steady import and export statistics. Lastly, the MEA region can show a sluggish growth rate owing to limited awareness levels and adherence to traditional medical practices. Browse Report @ https://www.marketresearchfuture.com/reports/drug- allergy-market-4033 4 www.marketresearchfuture.com

  5. Drug Allergy Market Drug Allergy Market Competitive Analysis Circassia, Bayer, MAGNA Pharmaceuticals, Inc., Stallergenes Greer, HAL Allergy Group, AstraZeneca, Johnson & Johnson Services, Inc., and others are major players operating in the global drug allergy market. July, 2017: AstraZeneca and Merck & Co., Inc. entered a global strategic oncology collaboration to co- develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment. The strategic collaboration is expected to further increase the number of treatment options available to patients. Ask Questions To The Experts @ https://www.marketresearchfuture.com/enquiry/4033 5 www.marketresearchfuture.com

  6. ABOUT US MARKET RESEARCH FUTURE At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information kindly visit www.marketresearchfuture.com or contact us at info@marketresearchfuture.com Copyright © 2018 Market Research Future All Rights Reserved. This document contains highly confidential information and is the sole property of Market Research Future. No part of it may be circulated, copied, quoted, or otherwise reproduced without the written approval of Market Research Future. 6 www.marketresearchfuture.com

  7. THANK YOU MARKET RESEARCH FUTURE sales@marketresearchfuture.com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) 7 www.marketresearchfuture.com

More Related